About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Andrew Fadden
Chief Business Officer
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer

Board of Directors

Scientific Advisors & Founders

Investors

David Watson

Chief Operating Officer

David joined Enara Bio in January 2019 and brings over 30 years of industry experience in functional operations, asset management and executive leadership.

David came to Enara Bio after a successful tenure as VP, Program Leadership at Immunocore where he was able to rapidly build their overall program leadership capability and take responsibility for the lead immuno-oncology program. Previously, David has held a variety of leadership roles within early/late stage clinical development operations in global pharmaceutical companies, including VP, Program Leadership and Management at Biogen. David has been instrumental in successfully building and leading local/regional/global teams, managing external relationships, and driving operational and strategic drug development in both Oncology and Neurology therapeutic areas.

David holds a first-class degree in Biological Sciences (biotechnology) from North East Surrey College of Technology.